Mode
Text Size
Log in / Sign up
Phase 1 Completed N=69 Treatment

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

Neoplasms
Source: ClinicalTrials.gov NCT02783300 ↗
Enrolled (actual)
69
Serious AEs
42.8%
Results posted
Mar 2025
Primary outcomePrimary: Part 1: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 1; 1; 1; 1 Participants

Summary

This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent solid tumors, as well as clinical activity in participants with a subset of solid tumors and non-Hodgkin's lymphoma (NHL).

Outcome Measures

OutcomeResultp-value
PRIMARY
Part 1: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
1; 1; 1; 1; 7; 3
PRIMARY
Part 1: Number of Participants Withdrawn Due to AEs
0; 0; 0; 0; 2; 0
PRIMARY
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
0; 0; 0; 0; 0; 1
PRIMARY
Part 1: Number of Participants With Dose Modifications of GSK3326595
1; 1; 1; 1; 5; 3
PRIMARY
Part 1: Number of Participants With Worst Case Change From Baseline in Clinical Chemistry Parameters
0; 0; 0; 0; 2; 0
PRIMARY
Part 1: Number of Participants With Worst Case Change From Baseline in Hematology Parameters
0; 0; 0; 0; 0; 0
PRIMARY
Part 1: Number of Participants With Worst Case Change From Baseline in Coagulation Parameters
0; 0; 0; 0; 0; 0
PRIMARY
Part 1: Number of Participants With Worst Case Change From Baseline in Urinalysis Parameters
0; 1; 0; 1; 5; 2
PRIMARY
Part 1: Changes From Baseline in Urine Potential of Hydrogen (pH)
5.00; 5.50; 7.00; 6.50; 6.00; 6.17
PRIMARY
Part 1: Changes From Baseline in Urine Specific Gravity
1.02; 1.03; 1.01; 1.02; 1.02; 1.02
PRIMARY
Part 1: Number of Participants With Maximum Grade Worst Case Increase Post-baseline Relative to Baseline in Vital Signs
0; 0; 0; 0; 1; 0
PRIMARY
Part 3: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
9; 5
PRIMARY
Part 3: Number of Participants Withdrawn Due to AEs
1
PRIMARY
Part 3: Number of Participants With Dose Modifications of GSK3326595 and Pembrolizumab
1; 0; 1; 0
PRIMARY
Part 3: Number of Participants With Worst Case Change From Baseline in Clinical Chemistry Parameters
2; 3; 4; 3; 6; 0
PRIMARY
Part 3: Number of Participants With Worst Case Change From Baseline in Hematology Parameters
0; 9; 0; 0; 8; 1
PRIMARY
Part 3: Number of Participants With Worst Case Change From Baseline in Coagulation Parameters
1; 5; 3; 1; 6; 2
PRIMARY
Part 3: Number of Participants With Worst Case Change From Baseline in Urinalysis Parameters
7; 3; 8; 2; 7; 3
PRIMARY
Part 3: Changes From Baseline in Urine Potential of Hydrogen (pH)
5.60; 0.00; 0.38; 0.33; 0.33; 0.31
PRIMARY
Part 3: Changes From Baseline in Urine Specific Gravity
1.02; 0.00; -0.01; 0.00; -0.01; 0.00
PRIMARY
Part 3: Number of Participants With Maximum Worst-case Increase Post-baseline Relative to Baseline in Vital Signs
0; 6; 3; 0; 9; 0
SECONDARY
Part 2: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
22; 16; 27; 37; 28; 34
SECONDARY
Part 2: Number of Participants Withdrawn Due to AEs
4; 4; 4; 3; 1; 3
SECONDARY
Part 2: Number of Participants With Dose Modifications of GSK3326595
13; 12; 11; 22; 20; 28
SECONDARY
Part 2: Number of Participants With Worst Case Change From Baseline in Clinical Chemistry Parameters
1; 1; 0; 2; 1; 9
SECONDARY
Part 2: Number of Participants With Worst Case Change From Baseline in Hematology Parameters
0; 0; 0; 2; 2; 1
SECONDARY
Part 2: Number of Participants With Worst Case Change From Baseline in Coagulation Parameters
2; 0; 3; 0; 0; 1
SECONDARY
Part 2: Number of Participants With Worst Case Change From Baseline in Urinalysis Parameters
19; 10; 20; 28; 18; 20
SECONDARY
Part 2: Changes From Baseline in Urine Potential of Hydrogen (pH)
5.95; 6.19; 5.97; 6.35; 6.00; 6.15
SECONDARY
Part 2: Changes From Baseline in Urine Specific Gravity
1.02; 1.02; 1.02; 1.02; 1.02; 1.02
SECONDARY
Part 2: Number of Participants With Maximum Grade Worst Case Increase Post-baseline Relative to Baseline in Vital Signs
0; 3; 2; 3; 2; 6
SECONDARY
Part 1: Maximum Observed Plasma Concentration (Cmax) of GSK3326595
14.1; 70.7; 288; 508; 653; 853
SECONDARY
Part 3: Maximum Observed Plasma Concentration (Cmax) of GSK3326595
291
SECONDARY
Part 1: Area Under the Plasma Concentration-time Curve (AUC) Extrapolated From Time Zero to Infinity (AUC[0-inf]) of GSK3326595
349; 926; 1710; 3240; 3800; 6760
SECONDARY
Part 3: Area Under the Plasma Concentration-time Curve (AUC) Extrapolated From Time Zero to Infinity (AUC[0-inf]) of GSK3326595
1770
SECONDARY
Part 1: AUC From Time Zero to the Last Quantifiable Concentration After Dosing (AUC[0-t]) of GSK3326595
249; 858; 1610; 3090; 3690; 6560
SECONDARY
Part 3: AUC From Time Zero to the Last Quantifiable Concentration After Dosing (AUC[0-t]) of GSK3326595
1480
SECONDARY
Part 1: AUC Over the Dosing Interval Tau (AUC[0-tau]) of GSK3326595
331; 924; 1710; 3120; 3730; 6600
SECONDARY
Part 3: AUC Over the Dosing Interval Tau (AUC[0-tau]) of GSK3326595
1640
SECONDARY
Part 1: Terminal Phase Half-life (t1/2) of GSK3326595
5.58; 2.66; 2.32; 4.82; 3.71; 4.46
SECONDARY
Part 3: Terminal Phase Half-life (t1/2) of GSK3326595
5.44
SECONDARY
Part 1: Oral Clearance (CL/F) of GSK3326595
71.7; 54.0; 58.5; 61.8; 79.0; 59.2
SECONDARY
Part 3: Oral Clearance (CL/F) of GSK3326595
56.4
SECONDARY
Part 1: Accumulation Ratio (AR) of GSK3326595
0.840; 0.719; 1.20; 1.34; 1.11; 1.34
SECONDARY
Part 3: Accumulation Ratio (AR) of GSK3326595
SECONDARY
Part 1: Time Invariance (TI) of GSK3326595
0.797; 0.717; 1.20; 1.29; 1.09; 1.31
SECONDARY
Part 3: Time Invariance (TI) of GSK3326595
SECONDARY
Part 1: Overall Response Rate (ORR) Based on RECIST 1.1
0; 0; 0; 0; 25.0; 0
SECONDARY
Part 2: Overall Response Rate (ORR) (Non-glioblastoma Multiforme [GBM] Cohorts)
0; 0; 2.7; 0; 2.9; 6.3
SECONDARY
Part 2: Six-month Progression Free Survival (PFS) Rate (GBM Cohort)
4
SECONDARY
Part 2: Duration of Response (DOR) (ACC Tablet Cohort)
NA
SECONDARY
Part 3: ORR Based on Immune-based RECIST (iRECIST) Criteria
SECONDARY
Part 2: ORR (GBM Cohort) Based on Response Assessment Neuro-Oncology (RANO) Working Group Criteria
SECONDARY
Part 2: ORR (Non-Hodgkin's Lymphoma (NHL) Cohorts) Based on Lugano Criteria
12.5; 10.0; 9.1
SECONDARY
Part 2: Overall Survival (OS) (ACC Tablet Cohort)
NA
SECONDARY
Part 2: Progression-free Survival
1.5; 3.6; 2.1; 3.2; 7.2; 7.1
SECONDARY
RP2D Phase: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
199; 14; 31; 92; 3; 11
SECONDARY
RP2D Phase: Number of Participants Withdrawn Due to AEs
25; 1; 3
SECONDARY
RP2D Phase: Number of Participants With Dose Modifications of GSK3326595
127; 9; 27; 123; 6; 11
SECONDARY
RP2D Phase: Number of Participants With Worst Case Change From Baseline in Clinical Chemistry Parameters
15; 1; 11; 165; 11; 20
SECONDARY
RP2D Phase: Number of Participants With Worst Case Change From Baseline in Hematology Parameters
5; 0; 0; 183; 13; 31
SECONDARY
RP2D Phase: Number of Participants With Worst Case Change From Baseline in Coagulation Parameters
6; 2; 3; 72; 4; 15
SECONDARY
RP2D Phase: Number of Participants With Worst Case Change From Baseline in Urinalysis Parameters
133; 10; 23; 64; 4; 8
SECONDARY
RP2D Phase: Changes From Baseline in Urine Potential of Hydrogen (pH)
6.11; 5.64; 5.98; -0.13; -0.04; -0.11
SECONDARY
RP2D Phase: Changes From Baseline in Urine Specific Gravity
1.02; 1.02; 1.02; 0.00; 0.00; 0.00
SECONDARY
RP2D Phase: Number of Participants With Worst-case Increase Post-baseline Relative to Baseline in Vital Signs
19; 0; 5; 124; 11; 17

Eligibility Criteria

Inclusion criteria

  • Males and females greater than or equal to (>=)18 years of age (at the time consent is obtained)
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 or 2
  • Diagnosis of non-resectable or metastatic solid malignancy (as defined in the protocol) or NHL
  • Presence of evaluable disease
  • Adequate organ function (as defined in the protocol)
  • Reproductive criteria (as defined in the protocol).

Exclusion Criteria

  • Malignancy attributed to prior solid organ transplant
  • Leptomeningeal disease, spinal cord compression, or brain metastases that require immediate central nervous system (CNS)-specific treatment in the opinion of the Investigator (for example [e.g.], for symptomatic disease)
  • History of a second malignancy, excluding non-melanoma skin cell cancer within the last three years
  • Evidence of severe or uncontrolled systemic diseases, or serious and/or pre-existing medical or other condition that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the Investigator
  • Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.
  • Select cardiac abnormalities (as defined in the protocol)
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
  • History of optic nerve neuropathy or neuritis.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02783300). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search